Literature DB >> 2002053

Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity.

W V Williams1, T Kieber-Emmons, J VonFeldt, M I Greene, D B Weiner.   

Abstract

The variable regions of antibody molecules bind antigens with high affinity and specificity. This binding is imparted largely by the hypervariable portions of the variable region. Hypervariable regions typically fold into reverse turn or loop structures. Peptides derived from antibody hypervariable region sequences can bind antigens with similar specificity, albeit with markedly lower affinity. In this study, cyclic and dimeric peptide analogs of an anti-idiotypic/antireceptor antibody hypervariable region were developed. This antibody (87.92.6) binds to reovirus type 3 receptors on cells as well as to a neutralizing anti-reovirus type 3 monoclonal antibody (9B.G5). The cyclic peptides were utilized to probe the optimal conformation for binding to both the receptor and 9B.G5. By dimerizing or constraining the conformation of these peptides, higher affinity binding was produced. By utilizing several different cyclic peptides, the optimal conformation for binding was established. The conformationally optimized cyclic peptide possessed greater than 40-fold higher affinity for the receptor and the idiotype than the linear analog. This study suggests that conformationally constrained and dimeric peptides derived from antibody hypervariable loop sequences can bind antigens (including receptors) with reasonable affinity. hypervariable loop sequences can bind antigens (including

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2002053

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Modulation of T cell responses with MHC-derived peptides.

Authors:  W V Williams; D B Weiner; M A Borofsky; D H Rubin; K Yui; M I Greene
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  Structural properties of a subset of nephritogenic anti-DNA antibodies.

Authors:  T Kieber-Emmons; M H Foster; W V Williams; M P Madaio
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

Review 3.  Targeting erbB receptors.

Authors:  Zheng Cai; Hongtao Zhang; Jing Liu; Alan Berezov; Ramachandran Murali; Qiang Wang; Mark I Greene
Journal:  Semin Cell Dev Biol       Date:  2010-09-17       Impact factor: 7.727

4.  Molecular determinants of polyreactive antibody binding: HCDR3 and cyclic peptides.

Authors:  Y J Deng; A L Notkins
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

5.  A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro.

Authors:  M Levi; M Sällberg; U Rudén; D Herlyn; H Maruyama; H Wigzell; J Marks; B Wahren
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

6.  Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

Authors:  J P Langedijk; N K Back; E Kinney-Thomas; C Bruck; M Francotte; J Goudsmit; R H Meloen
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 7.  Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein.

Authors:  W C Dougall; M I Greene
Journal:  Cell Biophys       Date:  1994

8.  Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles.

Authors:  J D Fontenot; V R Zacharopoulos; D M Phillips
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Granulocyte-macrophage colony-stimulating factor mimicry and receptor interactions.

Authors:  J M Von Feldt; C Monfardini; T Kieber-Emmons; D Voet; D B Weiner; W V Williams
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

10.  Potent peptidic fusion inhibitors of influenza virus.

Authors:  Rameshwar U Kadam; Jarek Juraszek; Boerries Brandenburg; Christophe Buyck; Wim B G Schepens; Bart Kesteleyn; Bart Stoops; Rob J Vreeken; Jan Vermond; Wouter Goutier; Chan Tang; Ronald Vogels; Robert H E Friesen; Jaap Goudsmit; Maria J P van Dongen; Ian A Wilson
Journal:  Science       Date:  2017-09-28       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.